title: Cytotoxic effects of statins and thiazolidinediones on meningioma cells.
abstract: Statins are inhibitors of the cholesterol synthesis pathway with pleiotropic effects, while thiazolidinediones (TDZ) are peroxisomal proliferator activator receptor γ (PPAR-γ) agonists with potent proapoptotic activity. For both groups of substances a cytotoxic effect against several human tumors is presumed. Direct comparison of several statins and TDZ has not been performed on meningioma cells until now. We compared the antiproliferative/cytotoxic effect of five statins, two TDZ, and their combinations on various human meningioma cell lines and nontumorous cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay, cell cycle analysis, and caspase-3 assay. Simvastatin (SMV) and its combination with the TDZ pioglitazone (PGZ) turned out to be the most effective treatment. After 96 h the 50% inhibition concentration (IC(50)) of SMV in MTT assays for two more sensitive meningioma cell lines (one benign and one malignant) was below 0.9 μM, while the IC(50) was 2.8 μM or higher for two other meningioma lines. Fluorescence-activated cell sorting (FACS) analysis suggested that MTT results mostly represented cytotoxic rather than antiproliferative effects. Strong caspase-3 induction suggested participation of intrinsic apoptosis in meningioma cell death. In contrast, SMV showed no substantial effects on fibroblasts and astrocytes. Addition of 40 μM PGZ significantly decreased the fraction of clonogenic cells in soft-agar assays, as compared with 2.8 μM SMV alone. Taken together, SMV showed a significant cytotoxic effect against human meningioma cells, which was moderately enhanced by PGZ.
authors.affiliation: Department of Neuropathology, Otto-von-Guericke University Magdeburg, Leipziger Str. 44, 39120 Magdeburg, Germany.
authors.forename: Sonja
authors.initials: S
authors.lastname: Gehring
authors.forename: Jorge Humberto
authors.initials: JH
authors.lastname: Tapia-Pérez
authors.forename: Elmar
authors.initials: E
authors.lastname: Kirches
authors.forename: Raimund
authors.initials: R
authors.lastname: Firsching
authors.forename: Gerburg
authors.initials: G
authors.lastname: Keilhoff
authors.forename: Thomas
authors.initials: T
authors.lastname: Schneider
authors.forename: Christian
authors.initials: C
authors.lastname: Mawrin
mesh_terms: D053148:Caspase 3 / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects; D003114:Colony-Forming Units Assay / Q000379:methods; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005434:Flow Cytometry / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000633:toxicity*; D008577:Meningeal Neoplasms / Q000473:pathology*; D008579:Meningioma / Q000473:pathology*; D014411:Neoplastic Stem Cells / Q000187:drug effects*; D045162:Thiazolidinediones / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045162:Thiazolidinediones; D053148:Caspase 3
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):215-26
references.pmid: 14522026
references.citation: Neuro Oncol. 2010 Aug;12(8):844-54
references.pmid: 20511185
references.citation: Mol Cancer Res. 2007 Jun;5(6):523-30
references.pmid: 17579114
references.citation: Surg Neurol. 1986 Nov;26(5):461-9
references.pmid: 3764651
references.citation: Am J Cardiol. 2005 Sep 5;96(5A):11F-23F
references.pmid: 16126019
references.citation: Clin Cancer Res. 2005 Jun 1;11(11):4074-82
references.pmid: 15930342
references.citation: Leuk Lymphoma. 2000 Dec;40(1-2):167-78
references.pmid: 11426618
references.citation: J Neurosci. 2003 Dec 3;23(35):11104-11
references.pmid: 14657168
references.citation: Carcinogenesis. 2005 May;26(5):883-91
references.pmid: 15705602
references.citation: Clin Cancer Res. 1999 Aug;5(8):2223-9
references.pmid: 10473109
references.citation: J Neuropathol Exp Neurol. 2005 Dec;64(12):1029-36
references.pmid: 16319713
references.citation: J Neurosurg. 2007 Feb;106(2):299-305
references.pmid: 17410715
references.citation: J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39
references.pmid: 13406590
references.citation: J Neurooncol. 2009 Dec;95(3):367-375
references.pmid: 19562258
references.citation: J Neurosci. 2000 Apr 15;20(8):2852-9
references.pmid: 10751437
references.citation: Strahlenther Onkol. 2008 Jan;184(1):48-53
references.pmid: 18188523
references.citation: J Biol Chem. 2004 Mar 5;279(10):8976-85
references.pmid: 14699130
references.citation: Neurosurg Focus. 2007;23(4):E11
references.pmid: 17961035
references.citation: Brain Pathol. 2008 Jan;18(1):62-70
references.pmid: 17924978
references.citation: Mol Pharmacol. 2006 Nov;70(5):1524-33
references.pmid: 16887936
references.citation: Brain Pathol. 2008 Apr;18(2):172-9
references.pmid: 18093250
references.citation: J Neurosurg. 2000 Oct;93(4):594-604
references.pmid: 11014537
references.citation: J Neurochem. 2004 Apr;89(1):168-78
references.pmid: 15030401
references.citation: Int J Cancer. 2006 Feb 1;118(3):773-9
references.pmid: 16094629
references.citation: J Neurochem. 2009 Jun;109(6):1779-90
references.pmid: 19457135
references.citation: Neoplasia. 2008 Nov;10(11):1204-12
references.pmid: 18953429
references.citation: J Neurooncol. 2008 Oct;90(1):9-17
references.pmid: 18566746
references.citation: Neoplasia. 2002 Jul-Aug;4(4):337-46
references.pmid: 12082550
references.citation: J Neurosurg. 1997 May;86(5):840-4
references.pmid: 9126900
references.citation: Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):598-603
references.pmid: 15681303
references.citation: Neurosci Lett. 2007 Apr 24;417(1):72-7
references.pmid: 17324516
references.citation: Arzneimittelforschung. 1997 Jan;47(1):29-35
references.pmid: 9037440
references.citation: J Neurooncol. 2002 Jan;56(2):133-42
references.pmid: 11995814
references.citation: Oncologist. 2006 Mar;11(3):306-15
references.pmid: 16549815
references.citation: J Neurooncol. 2008 Feb;86(3):273-83
references.pmid: 17928957
references.citation: J Clin Neurosci. 2008 Jul;15(7):764-8
references.pmid: 18406142
references.citation: J Biol Chem. 2001 Apr 13;276(15):12076-83
references.pmid: 11278531
references.citation: Clin Cancer Res. 1996 Mar;2(3):483-91
references.pmid: 9816194